$CELG Recent News The market puts a few feathers
Post# of 88914
Posted On: 02/25/2014 12:47:36 PM
$CELG Recent News
The market puts a few feathers in its cap 1:58 p.m. Jan. 23, 2014 - The Trading Deck
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Celgene's 2014 guidance falls below analyst views 12:19 p.m. Jan. 13, 2014 - MarketWatch.com
Clovis Oncology, seen as 'next ICPT,' jumps 5% 9:47 a.m. Jan. 13, 2014 - Victor Reklaitis
Intercept, Celgene on move amid J.P. Morgan event 9:20 a.m. Jan. 13, 2014 - Victor Reklaitis
Epizyme shares surge 65% after cancer therapy hits milestone 11:06 a.m. Jan. 7, 2014 - Russ Britt
Sirius soars; Twitter tumbles on downgrade 3:50 p.m. Jan. 6, 2014 - Wallace Witkowski
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Sorry, haters: Unloved stocks had a great year 7:41 a.m. Dec. 30, 2013 - Brett Arends
These S&P winners have room to grow in 2014 6:00 a.m. Dec. 23, 2013 - Jeff Reeves
Two growth stocks that look ready to fly 1:29 p.m. Dec. 12, 2013 - The Trading Deck
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
What the worst advisers are recommending 1:16 p.m. Nov. 21, 2013 - Mark Hulbert
Top performers’ top November bets 11:01 p.m. Nov. 3, 2013 - Mark Hulbert
Celgene raises earnings outlook as sales climb 7:27 a.m. Oct. 24, 2013 - MarketWatch.com
A bull market as typical as any other 11:23 a.m. Oct. 22, 2013 - The Trading Deck
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
Market uptrend bends, without cracking 11:55 a.m. Oct. 1, 2013 - Michael Ashbaugh
Market technicals bend, without cracking 11:38 a.m. Oct. 1, 2013 - Michael Ashbaugh
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck
Putting the biotech boom in perspective 12:54 p.m. Feb. 24, 2014 - Seeking Alpha
What To Buy: Celgene Corporation's Buy Recommendation Reiterated 9:00 a.m. Feb. 24, 2014 - TheStreet.com
Catalysts Drive These Stocks: Mara Goldstein 9:20 a.m. Feb. 21, 2014 - Seeking Alpha
Can CELG Clear Key Resistance? 9:00 a.m. Feb. 21, 2014 - RealMoney.com
Placenta Based Treatments Crowding Out Legacy Products In Wound Care 8:34 a.m. Feb. 21, 2014 - Seeking Alpha
Who Is Responsible For Biotech's Torrid Start to 2014? 4:03 p.m. Feb. 20, 2014 - TheStreet.com
REGN, BIIB And CELG, Pushing Drugs Industry Downward 12:04 p.m. Feb. 19, 2014 - TheStreet.com
Celgene Corporation (CELG): Today's Featured Health Care Winner 5:00 p.m. Feb. 18, 2014 - TheStreet.com
Celgene Plans Stock Split - Analyst Blog 5:34 p.m. Feb. 14, 2014 - Zacks.com
Big Pharma Will Find Good Hunting Among Early-Stage Biotechs: Dhesh Govender 11:56 a.m. Feb. 14, 2014 - Seeking Alpha
AbbVie Deserves More Respect 6:30 a.m. Feb. 14, 2014 - TheStreet.com
10-K: CELGENE CORP /DE/ 4:04 p.m. Feb. 13, 2014 - Edgar Online - (EDG = 10Q, 10K)
Market Wrap For February 13: Markets Close Higher; Nasdaq on a Six Day Winning Streak 3:50 p.m. Feb. 13, 2014 - benzinga.com
Regenerative Medicine Finally Gets Some Respect: Reni Benjamin 9:23 a.m. Feb. 13, 2014 - Seeking Alpha
IPO Preview: Concert Pharmaceuticals 1:00 a.m. Feb. 13, 2014 - Seeking Alpha
Jim Cramer's 6 Stocks in 60 Seconds: BUD S LNG VJET SGEN CROX 5:08 p.m. Feb. 12, 2014 - TheStreet.com
Short Sellers Shy Away From Biotechs 6:04 a.m. Feb. 12, 2014 - 247WallSt.com
Celgene Corporation Continues With Buy Recommendation 9:00 a.m. Feb. 11, 2014 - TheStreet.com
Health Canada Approves (Pr)POMALYST(TM) (Pomalidomide Capsules) Providing New Hope For Patients With Progressive Multiple Myeloma 6:30 a.m. Feb. 11, 2014 - CNW Group
You Can No Longer Ignore Biotech 4:32 p.m. Feb. 7, 2014 - GuruFocus.com
Celgene Corporation Board of Directors Recommends to Our Stockholders a Two-for-One Stock Split 7:30 a.m. Feb. 13, 2014 - BusinessWire - BZX
Celgene Corporation to Present at Investor Conferences in February and March 8:30 a.m. Feb. 11, 2014 - BusinessWire - BZX
Grant & Eisenhofer Represents Whistleblower Accusing Celgene Corp. of Off-Label Marketing of High-Risk Cancer Drugs Derived from Thalidomide 2:11 p.m. Feb. 6, 2014 - PR Newswire - PRF
Critical Alerts For Baidu.com, Endo Pharmaceuticals, Mattel, Celgene, and Tyson Foods Released By InvestorsObserver 9:31 a.m. Feb. 4, 2014 - PR Newswire - PRF
Celgene Reports Fourth Quarter and Full Year 2013 Operating and Financial Results 7:32 a.m. Jan. 30, 2014 - BusinessWire - BZX
Celgene Corporation to Announce Fourth Quarter and Full Year 2013 Results on January 30, 2014 8:30 a.m. Jan. 22, 2014 - BusinessWire - BZX
Celgene Corporation Announces 2014 Financial Outlook and Preliminary 2013 Results 11:29 a.m. Jan. 13, 2014 - BusinessWire - BZX
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
ABRAXANE(R) Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer 6:01 a.m. Jan. 7, 2014 - BusinessWire
Critical Alerts For Google, Celgene, Salesforce.com, Chesapeake Energy, and Endo Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Jan. 3, 2014 - PR Newswire
Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference 8:29 a.m. Jan. 2, 2014 - BusinessWire
Presentation of Clinical Study Data, Prestigious Accolades, and Acquisitions - Research Report on Celgene, UnitedHealth, AstraZeneca, Mylan, and Valeant 8:00 a.m. Dec. 25, 2013 - PR Newswire
Clinical Study Data Presentation, Product Launches, Technology Deployments, and Stock Price Movements - Research Report on Celgene, Mylan, Valeant, Health Management, and CareFusion 8:00 a.m. Dec. 17, 2013 - PR Newswire
Atara Biotherapeutics Secures $38.5 Million Series B Financing 7:00 a.m. Dec. 17, 2013 - BusinessWire
Agios Advances Cancer Metabolism Collaboration with Celgene 8:16 a.m. Dec. 11, 2013 - BusinessWire
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH 7:00 p.m. Dec. 10, 2013 - BusinessWire
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH 8:30 a.m. Dec. 10, 2013 - BusinessWire
REVLIMID(R) (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response 7:30 p.m. Dec. 9, 2013 - BusinessWire
Stock Price Movements, Completed Acquisitions, and New Clinical Studies - Research Report on UnitedHealth Group, Mylan, St. Jude Medical, and Cigna 8:00 a.m. Dec. 9, 2013 - PR Newswire
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH 9:37 p.m. Dec. 7, 2013 - BusinessWire
The market puts a few feathers in its cap 1:58 p.m. Jan. 23, 2014 - The Trading Deck
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Celgene's 2014 guidance falls below analyst views 12:19 p.m. Jan. 13, 2014 - MarketWatch.com
Clovis Oncology, seen as 'next ICPT,' jumps 5% 9:47 a.m. Jan. 13, 2014 - Victor Reklaitis
Intercept, Celgene on move amid J.P. Morgan event 9:20 a.m. Jan. 13, 2014 - Victor Reklaitis
Epizyme shares surge 65% after cancer therapy hits milestone 11:06 a.m. Jan. 7, 2014 - Russ Britt
Sirius soars; Twitter tumbles on downgrade 3:50 p.m. Jan. 6, 2014 - Wallace Witkowski
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Sorry, haters: Unloved stocks had a great year 7:41 a.m. Dec. 30, 2013 - Brett Arends
These S&P winners have room to grow in 2014 6:00 a.m. Dec. 23, 2013 - Jeff Reeves
Two growth stocks that look ready to fly 1:29 p.m. Dec. 12, 2013 - The Trading Deck
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
What the worst advisers are recommending 1:16 p.m. Nov. 21, 2013 - Mark Hulbert
Top performers’ top November bets 11:01 p.m. Nov. 3, 2013 - Mark Hulbert
Celgene raises earnings outlook as sales climb 7:27 a.m. Oct. 24, 2013 - MarketWatch.com
A bull market as typical as any other 11:23 a.m. Oct. 22, 2013 - The Trading Deck
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
Market uptrend bends, without cracking 11:55 a.m. Oct. 1, 2013 - Michael Ashbaugh
Market technicals bend, without cracking 11:38 a.m. Oct. 1, 2013 - Michael Ashbaugh
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck
Putting the biotech boom in perspective 12:54 p.m. Feb. 24, 2014 - Seeking Alpha
What To Buy: Celgene Corporation's Buy Recommendation Reiterated 9:00 a.m. Feb. 24, 2014 - TheStreet.com
Catalysts Drive These Stocks: Mara Goldstein 9:20 a.m. Feb. 21, 2014 - Seeking Alpha
Can CELG Clear Key Resistance? 9:00 a.m. Feb. 21, 2014 - RealMoney.com
Placenta Based Treatments Crowding Out Legacy Products In Wound Care 8:34 a.m. Feb. 21, 2014 - Seeking Alpha
Who Is Responsible For Biotech's Torrid Start to 2014? 4:03 p.m. Feb. 20, 2014 - TheStreet.com
REGN, BIIB And CELG, Pushing Drugs Industry Downward 12:04 p.m. Feb. 19, 2014 - TheStreet.com
Celgene Corporation (CELG): Today's Featured Health Care Winner 5:00 p.m. Feb. 18, 2014 - TheStreet.com
Celgene Plans Stock Split - Analyst Blog 5:34 p.m. Feb. 14, 2014 - Zacks.com
Big Pharma Will Find Good Hunting Among Early-Stage Biotechs: Dhesh Govender 11:56 a.m. Feb. 14, 2014 - Seeking Alpha
AbbVie Deserves More Respect 6:30 a.m. Feb. 14, 2014 - TheStreet.com
10-K: CELGENE CORP /DE/ 4:04 p.m. Feb. 13, 2014 - Edgar Online - (EDG = 10Q, 10K)
Market Wrap For February 13: Markets Close Higher; Nasdaq on a Six Day Winning Streak 3:50 p.m. Feb. 13, 2014 - benzinga.com
Regenerative Medicine Finally Gets Some Respect: Reni Benjamin 9:23 a.m. Feb. 13, 2014 - Seeking Alpha
IPO Preview: Concert Pharmaceuticals 1:00 a.m. Feb. 13, 2014 - Seeking Alpha
Jim Cramer's 6 Stocks in 60 Seconds: BUD S LNG VJET SGEN CROX 5:08 p.m. Feb. 12, 2014 - TheStreet.com
Short Sellers Shy Away From Biotechs 6:04 a.m. Feb. 12, 2014 - 247WallSt.com
Celgene Corporation Continues With Buy Recommendation 9:00 a.m. Feb. 11, 2014 - TheStreet.com
Health Canada Approves (Pr)POMALYST(TM) (Pomalidomide Capsules) Providing New Hope For Patients With Progressive Multiple Myeloma 6:30 a.m. Feb. 11, 2014 - CNW Group
You Can No Longer Ignore Biotech 4:32 p.m. Feb. 7, 2014 - GuruFocus.com
Celgene Corporation Board of Directors Recommends to Our Stockholders a Two-for-One Stock Split 7:30 a.m. Feb. 13, 2014 - BusinessWire - BZX
Celgene Corporation to Present at Investor Conferences in February and March 8:30 a.m. Feb. 11, 2014 - BusinessWire - BZX
Grant & Eisenhofer Represents Whistleblower Accusing Celgene Corp. of Off-Label Marketing of High-Risk Cancer Drugs Derived from Thalidomide 2:11 p.m. Feb. 6, 2014 - PR Newswire - PRF
Critical Alerts For Baidu.com, Endo Pharmaceuticals, Mattel, Celgene, and Tyson Foods Released By InvestorsObserver 9:31 a.m. Feb. 4, 2014 - PR Newswire - PRF
Celgene Reports Fourth Quarter and Full Year 2013 Operating and Financial Results 7:32 a.m. Jan. 30, 2014 - BusinessWire - BZX
Celgene Corporation to Announce Fourth Quarter and Full Year 2013 Results on January 30, 2014 8:30 a.m. Jan. 22, 2014 - BusinessWire - BZX
Celgene Corporation Announces 2014 Financial Outlook and Preliminary 2013 Results 11:29 a.m. Jan. 13, 2014 - BusinessWire - BZX
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
ABRAXANE(R) Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer 6:01 a.m. Jan. 7, 2014 - BusinessWire
Critical Alerts For Google, Celgene, Salesforce.com, Chesapeake Energy, and Endo Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Jan. 3, 2014 - PR Newswire
Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference 8:29 a.m. Jan. 2, 2014 - BusinessWire
Presentation of Clinical Study Data, Prestigious Accolades, and Acquisitions - Research Report on Celgene, UnitedHealth, AstraZeneca, Mylan, and Valeant 8:00 a.m. Dec. 25, 2013 - PR Newswire
Clinical Study Data Presentation, Product Launches, Technology Deployments, and Stock Price Movements - Research Report on Celgene, Mylan, Valeant, Health Management, and CareFusion 8:00 a.m. Dec. 17, 2013 - PR Newswire
Atara Biotherapeutics Secures $38.5 Million Series B Financing 7:00 a.m. Dec. 17, 2013 - BusinessWire
Agios Advances Cancer Metabolism Collaboration with Celgene 8:16 a.m. Dec. 11, 2013 - BusinessWire
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH 7:00 p.m. Dec. 10, 2013 - BusinessWire
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH 8:30 a.m. Dec. 10, 2013 - BusinessWire
REVLIMID(R) (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response 7:30 p.m. Dec. 9, 2013 - BusinessWire
Stock Price Movements, Completed Acquisitions, and New Clinical Studies - Research Report on UnitedHealth Group, Mylan, St. Jude Medical, and Cigna 8:00 a.m. Dec. 9, 2013 - PR Newswire
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH 9:37 p.m. Dec. 7, 2013 - BusinessWire
(0)
(0)Scroll down for more posts ▼